<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846361</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2021-031</org_study_id>
    <nct_id>NCT04846361</nct_id>
  </id_info>
  <brief_title>Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis</brief_title>
  <official_title>The Effectiveness of Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis- a Randomized Double Blind Controlled Trial With Microbial Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of vaginal hygiene wash versus placebo as adjunct treatment&#xD;
      with oral metronidazole in treatment of women with bacterial vaginosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial comparing the trial hygiene wash against placebo wash&#xD;
      as adjunct treatment with oral metronidazole in women with bacterial vaginosis, with&#xD;
      microbial analysis of vaginal flora compared to healthy control women&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>hygiene wash plus antibiotic, placebo wash plus antibiotic</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>the trial hygiene wash and placebo wash are labelled A or B in identical packaging by manufacturer's company and blinded from both participants and investigators and only revealed at the end of data completion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial vaginosis cure rate</measure>
    <time_frame>2 weeks after treatment</time_frame>
    <description>Percentage of participants who have negative bacterial vaginosis (BV) blue test after completed treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analog scale of symptoms before treatment</measure>
    <time_frame>before treatment</time_frame>
    <description>self-evaluation of symptom using Visual analog scale (VAS) scale 0 to 10 based on questionnaire, 5 symptoms assessed are 1) level of comfort in the genital region, 2) malodorous external genitalia, 3) comfort in sexual intercourse, 4) satisfaction regarding intimate hygiene, and 5) self-esteem</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analog scale of symptoms after treatment</measure>
    <time_frame>2 weeks after treatment</time_frame>
    <description>self-evaluation of symptom using Visual analog scale (VAS) scale 0 to 10 based on questionnaire, 5 symptoms assessed are 1) level of comfort in the genital region, 2) malodorous external genitalia, 3) comfort in sexual intercourse, 4) satisfaction regarding intimate hygiene, and 5) self-esteem</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial profile of vaginal flora before treatment</measure>
    <time_frame>Before treatment</time_frame>
    <description>DNA quantitative polymerase chain reaction (qPCR) array analysis of vaginal swab taken before treatment which includes Lactobacillus, Gardnerella, Prevotella, Candida, and Trichomonas vaginalis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial profile of vaginal flora after treatment</measure>
    <time_frame>2 weeks after treatment</time_frame>
    <description>DNA quantitative polymerase chain reaction (qPCR) array analysis of vaginal swab taken before treatment which includes Lactobacillus, Gardnerella, Prevotella, Candida, and Trichomonas vaginalis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines concentration before treatment</measure>
    <time_frame>before treatment</time_frame>
    <description>Concentration of cytokines (interleukins (IL-6, IL-8, IL-10), tumor necrosis factor (TNF-alpha) all in pg/mL at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines concentration after treatment</measure>
    <time_frame>2 weeks after treatment</time_frame>
    <description>Concentration of cytokines (interleukins (IL-6, IL-8, IL-10), tumor necrosis factor (TNF-alpha) all in pg/ml after completed treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of symptoms 1 month after completed treatment</measure>
    <time_frame>1 month after completed treatment</time_frame>
    <description>Self-rated symptoms using visual analog scale (VAS) scale 0 to 10 based on questionnaire, 5 symptoms assessed are 1) level of comfort in the genital region, 2) malodorous external genitalia, 3) comfort in sexual intercourse, 4) satisfaction regarding intimate hygiene, and 5) self-esteem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial analysis of vaginal flora 1 month after completed treatment</measure>
    <time_frame>1 month after completed treatment</time_frame>
    <description>DNA quantitative polymerase chain reaction (qPCR) array analysis of vaginal swab taken before treatment which includes Lactobacillus, Gardnerella, Prevotella, Candida, and Trichomonas vaginalis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Hygiene wash plus metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hygiene wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo wash plus metronidazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Asymptomatic healthy women with BV negative test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vaginal hygiene wash</intervention_name>
    <description>vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash</description>
    <arm_group_label>Hygiene wash plus metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo wash</intervention_name>
    <description>placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume</description>
    <arm_group_label>placebo wash plus metronidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. premenopausal women who are sexually active 2.willing to use hygiene wash together&#xD;
             with prescribed oral antibiotics 3. able to undergo pelvic examination for sampling of&#xD;
             vaginal discharge&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Unable to comply with pelvic examination or hygiene wash 2. Concurrent use of&#xD;
             hormonal treatment or antibiotic therapy 3. Intrauterine device either copper or&#xD;
             levonorgestrel-releasing system 4. Women with known diabetes mellitus 5. Pregnant&#xD;
             women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>non-pregnant women with bacterial vaginosis</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nur Azurah Abdul Ghani</last_name>
    <role>Principal Investigator</role>
    <affiliation>The National University of Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nurliyana Abdul Razak</last_name>
    <phone>60391455555</phone>
    <phone_ext>5950</phone_ext>
    <email>lilin_yana@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Izyan Atiqah Zakaria, B.Med</last_name>
    <phone>60391455555</phone>
    <phone_ext>5950</phone_ext>
    <email>yantz2002@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, Romero R. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011 Apr;118(5):533-49. doi: 10.1111/j.1471-0528.2010.02840.x. Epub 2011 Jan 20. Review.</citation>
    <PMID>21251190</PMID>
  </reference>
  <reference>
    <citation>Eusaph AZ, Nighat R, Arshad A. Lactacyd FH as an adjuvant therapy for vulvovaginal infections in Pakistani women: FRESH study, a satisfaction survey. J Pak Med Assoc. 2016 May;66(5):521-7.</citation>
    <PMID>27183928</PMID>
  </reference>
  <reference>
    <citation>Bai G, Gajer P, Nandy M, Ma B, Yang H, Sakamoto J, Blanchard MH, Ravel J, Brotman RM. Comparison of storage conditions for human vaginal microbiome studies. PLoS One. 2012;7(5):e36934. doi: 10.1371/journal.pone.0036934. Epub 2012 May 24.</citation>
    <PMID>22655031</PMID>
  </reference>
  <reference>
    <citation>Hallmaier-Wacker LK, Lueert S, Roos C, Knauf S. The impact of storage buffer, DNA extraction method, and polymerase on microbial analysis. Sci Rep. 2018 Apr 19;8(1):6292. doi: 10.1038/s41598-018-24573-y.</citation>
    <PMID>29674641</PMID>
  </reference>
  <results_reference>
    <citation>Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018 Jul;298(1):139-145. doi: 10.1007/s00404-018-4771-z. Epub 2018 Apr 10.</citation>
    <PMID>29637269</PMID>
  </results_reference>
  <results_reference>
    <citation>Bahamondes MV, Portugal PM, Brolazo EM, Sim√µes JA, Bahamondes L. Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. Rev Assoc Med Bras (1992). 2011 Jul-Aug;57(4):415-20.</citation>
    <PMID>21876923</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal hygiene wash</keyword>
  <keyword>bacterial vaginosis</keyword>
  <keyword>microbial analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>clinical data sheet containing demographics, data collection (VAS score of symptoms, BV blue test)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>20 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

